Skip to main content
    A

    Abbott Laboratories (ABT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $104.89
    +1.19 (+1.15%)

    Market Cap: $180.63B

    Last updated: Oct 27, 2026 at 10:41 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    98%(39/40)
    Avg Surprise
    +6.39%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$1.68
    Range$1.65 - $1.71
    26 analysts
    Revenue Consensus
    $13.4B
    Range$12.6B - $13.5B
    14 analysts
    Period ending Mar 31, 2027
    EPS Consensus$1.26
    Range$1.21 - $1.42
    17 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$1.29-2.3%
    60d ago$1.29-2.2%
    30d ago$1.29-2.2%
    7d ago$1.29-2.2%
    Current$1.26
    Revenue Consensus
    $12.7B
    Range$12.4B - $13.0B
    16 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 27EST
    		-$1.26---
    Dec 26EST
    		-$1.68---
    Sep 26
    Reported Oct 21
    		$1.42$1.43-0.70%Miss+9.2%
    Jun 26
    Reported Jul 16
    		$1.31$1.28+2.34%Beat+4.0%
    Mar 26
    Reported Apr 16
    		$1.15$1.15+0.00%Beat+5.5%
    Dec 25
    Reported Jan 22
    		$1.50$1.49+0.67%Beat+11.9%
    Sep 25
    Reported Oct 15
    		$1.30$1.30+0.00%Beat+7.4%
    Jun 25
    Reported Jul 17
    		$1.26$1.26+0.00%Beat+10.5%
    Mar 25
    Reported Apr 16
    		$1.09$1.07+1.87%Beat+11.2%
    Dec 24
    Reported Jan 22
    		$1.34$1.34+0.00%Beat+12.6%
    Sep 24
    Reported Oct 16
    		$1.21$1.20+0.83%Beat+6.1%
    Jun 24
    Reported Jul 18
    		$1.14$1.10+3.64%Beat+5.6%
    Mar 24
    Reported Apr 17
    		$0.98$0.95+3.16%Beat-4.9%
    Dec 23
    Reported Jan 24
    		$1.19$1.19+0.00%Beat+15.5%
    Sep 23
    Reported Oct 18
    		$1.14$1.10+3.64%Beat-0.9%
    Jun 23
    Reported Jul 20
    		$1.08$1.05+2.86%Beat-24.5%
    Mar 23
    Reported Apr 19
    		$1.03$0.99+4.04%Beat-40.5%
    Dec 22
    Reported Jan 25
    		$1.03$0.94+9.57%Beat-22.0%
    Sep 22
    Reported Oct 19
    		$1.15$0.94+22.34%Beat-17.9%
    Jun 22
    Reported Jul 20
    		$1.43$1.14+25.44%Beat+22.2%
    Mar 22
    Reported Apr 20
    		$1.73$1.46+18.49%Beat+31.1%
    Dec 21
    Reported Jan 26
    		$1.32$1.21+9.09%Beat-9.0%
    Sep 21
    Reported Oct 20
    		$1.40$0.95+47.37%Beat+42.9%
    Jun 21
    Reported Jul 22
    		$1.17$1.02+14.71%Beat+105.3%
    Mar 21
    Reported Apr 20
    		$1.32$1.27+3.94%Beat+103.1%
    Dec 20
    Reported Jan 27
    		$1.45$1.35+7.41%Beat+52.6%
    Sep 20
    Reported Oct 21
    		$0.98$0.91+7.69%Beat+16.7%
    Jun 20
    Reported Jul 16
    		$0.57$0.42+35.71%Beat-30.5%
    Mar 20
    Reported Apr 16
    		$0.65$0.61+6.56%Beat+3.2%
    Dec 19
    Reported Jan 22
    		$0.95$0.95+0.00%Beat+17.3%
    Sep 19
    Reported Oct 16
    		$0.84$0.84+0.00%Beat+12.0%
    Jun 19
    Reported Jul 17
    		$0.82$0.80+2.50%Beat+12.3%
    Mar 19
    Reported Apr 17
    		$0.63$0.62+1.61%Beat+6.8%
    Dec 18
    Reported Jan 23
    		$0.81$0.81+0.00%Beat+9.5%
    Sep 18
    Reported Oct 17
    		$0.75$0.75+0.00%Beat+13.6%
    Jun 18
    Reported Jul 18
    		$0.73$0.71+2.82%Beat+17.7%
    Mar 18
    Reported Apr 18
    		$0.59$0.58+1.72%Beat+22.9%
    Dec 17
    Reported Jan 24
    		$0.74$0.73+1.37%Beat+13.8%
    Sep 17
    Reported Oct 18
    		$0.66$0.65+1.54%Beat-
    Jun 17
    Reported Jul 20
    		$0.62$0.61+1.64%Beat-
    Mar 17
    Reported Apr 19
    		$0.48$0.43+11.63%Beat-
    Dec 16
    Reported Jan 25
    		$0.65$0.65+0.00%Beat-

    Dividends

    Dividend Metrics

    Forward Yield2.40%
    Forward Annual Dividend$2.52
    Payout Ratio44.28%
    FrequencyQuarterly
    Pay MonthsFeb, May, Aug, Nov

    Growth

    3Y CAGR+7.87%
    5Y CAGR+10.38%
    ABT dividend history and ex-dividend datesRun ABT in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio19.50EV/EBITDA18.41x
    Price/FCF23.33xFCF Yield4.29%
    Profitability
    Profit Margin9.75%Operating Margin11.30%
    ROE10.60%ROIC6.87%
    Financial Health
    Debt/Equity0.64xInterest Coverage10.40x
    Current Ratio1.38xQuick Ratio0.97x
    Trading Statistics
    Beta0.58Avg Volume10.08M
    52-Week High$128.8352-Week Low$80.89

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$103.20
    SMA 20$100.85
    SMA 50$104.51
    SMA 200$101.25
    EMA 10$102.79
    EMA 20$102.23
    EMA 50$102.38
    EMA 200$104.53

    MACD

    Line: 0.31Signal: -0.26Hist: 0.58

    ADX

    ADX: 20.2+DI: 19.2-DI: 21.4

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down36.0
    PSAR$106.01

    Bollinger Bands

    Upper Band$106.50
    Lower Band$95.19
    %B Position1121%(Upper)
    Band Width0.86

    RSI (14-Day)

    Neutral
    58.1

    Momentum Oscillators

    Stoch %K71.0
    Stoch %D62.8
    Williams %R-16.0
    ROC (10d)3.6%
    Momentum3.68
    CCI (20d)100.4
    MFI (14d)54.8

    Volatility Measures

    ATR (14d)$2.91(2.8%)
    StdDev (20d)2.83
    Hist Vol24.5%(Moderate)

    Volume Flow

    VWAP$104.34
    OBV-146.6M
    AD Line-3.1B
    CMF (20d)-0.172

    Volume Metrics

    Avg Vol (20d)10.2M
    Vol Ratio0.8x
    VWMA (20d)$100.83

    Pivot Points

    R3$107.05
    R2$105.53
    R1$104.61
    Pivot Point$103.09
    S1$102.17
    S2$100.65
    S3$99.73

    Advanced Oscillators

    TSI3.44
    Ultimate Osc49.5
    KST-7.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$12.59B$11.16B$11.46B$11.37B$11.14B$10.36B$10.97B$10.63B$10.38B$9.96B$10.24B$10.14B
    Cost of Revenue$5.33B$4.89B$4.92B$5.08B$4.85B$4.47B$4.94B$4.70B$4.60B$4.46B$4.56B$4.61B
    Gross Profit$7.27B$6.27B$6.54B$6.29B$6.29B$5.89B$6.03B$5.94B$5.77B$5.50B$5.68B$5.54B
    Operating Expenses$5.58B$4.93B$4.29B$4.24B$4.24B$4.20B$4.12B$4.08B$4.11B$4.12B$3.90B$3.89B
    R&D$892.00M$767.00M$735.00M$766.00M$725.00M$716.00M$749.00M$713.00M$698.00M$684.00M$700.00M$672.00M
    SG&A$4.03B$3.74B$3.13B$3.05B$3.09B$3.06B$2.91B$2.90B$2.94B$2.96B$2.72B$2.72B
    Operating Income$1.69B$1.34B$2.25B$2.06B$2.05B$1.69B$1.91B$1.86B$1.67B$1.39B$1.78B$1.65B
    Interest Income$52.00M$106.00M$78.00M$77.00M$71.00M$82.00M$91.00M$91.00M$82.00M$80.00M$89.00M$97.00M
    Interest Expense$351.00M$174.00M$120.00M$121.00M$121.00M$131.00M$136.00M$142.00M$140.00M$141.00M$159.00M$166.00M
    Income Before Tax$1.52B$1.45B$2.36B$2.18B$2.15B$1.78B$2.03B$1.94B$1.61B$1.44B$1.79B$1.67B
    Income Tax Expense$596.00M$372.00M$582.00M$536.00M$371.00M$453.00M$-7,199,000,000$294.00M$305.00M$211.00M$201.00M$235.00M
    Net Income$928.00M$1.08B$1.78B$1.64B$1.78B$1.32B$9.23B$1.65B$1.30B$1.23B$1.59B$1.44B
    EBITDA$2.88B$2.32B$3.19B$3.02B$2.98B$2.58B$2.88B$2.79B$2.47B$2.30B$2.68B$2.56B
    EBIT$1.82B$1.52B$2.40B$2.22B$2.20B$1.83B$2.08B$1.99B$1.67B$1.50B$1.86B$1.74B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    Abbott: The Market Priced the Dent and Forgot the Cargo

    Market punished Abbott - stock down ~34% from 52-week high $139.06 to ~$91, yet TTM revenue $45.1B, gross margin 56.4%, operating cash flow $9.46B and free cash flow $7.38B ($4.22/sh, 4.85% FCF yield) Closed oncology acquisition for ~$21B equity (~$23B incl assumed debt), funded with $20B notes...

    Glenn Ford
    •
    6/9/26
    •
    271
    Dividend Kings, medical-technology, value investing
    Also mentions:
    MDTJNJ

    Intuit (INTU): The Stock Broke Before the Business Did

    INTU down ~56% to ~$331 from >$800, trading well below the 200-day at $554 - thesis: market priced collapse, but business intact; staged Strong Buy, blended fair value $480, 12-month target $430, margin of safety ~31% Buy schedule - start a partial near $331, add on a defended retest low $300s...

    Glenn Ford
    •
    6/2/26
    •
    255
    Software Stocks, FinTech, value investing
    Also mentions:
    ADPPAYXBILL

    The Aristocrat Nobody Wanted: Why (MDT) Is Worth a Second Look Right Now

    (MDT) has raised its dividend for 48 consecutive years, yet trades at just 14x forward earnings. On a trailing basis it is 24x vs. (ISRG) at 57x and (SYK) at 40x. The 5-year dividend CAGR is 4.4%, slowing to 2.0% over three years. This is a yield anchor at 3.3%...

    Glenn Ford
    •
    4/8/26
    •
    165
    dividend aristocrats, value investing, Medical Devices
    Also mentions:
    ISRGABTSYK

    Why TransMedics Stock is a Buy for Long-Term Investors

    TransMedics is replacing a 60-year-old organ-transport method with its FDA-approved OCS platform, which keeps hearts, lungs, and livers alive and functioning during transit — a massive step-change in reliability and outc Business model now prints cash...

    Glenn Ford
    •
    11/14/25
    •
    295
    medical-technology, healthcare-innovation, organ-transplant, growth-stocks
    Also mentions:
    ISRGSYKMDTABTEW

    Government Contracts

    Gov Obligations (TTM)
    $137.48M
    Gov Obligations / Revenue
    0.3%
    Obligations YoY
    3.3%
    Active Awards
    3,044
    New Awards (TTM)
    2,790
    Avg Remaining Term
    18.5 mo

    Top agency: Department of Veterans Affairs at 64.8% of trailing twelve month obligations across 10 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24126N0013Department of Veterans AffairsDepartment of Veterans Affairs$4.33MOct 1, 2025
    36C26126N0108Department of Veterans AffairsDepartment of Veterans Affairs$4.00MOct 1, 2025
    36C24826N0460Department of Veterans AffairsDepartment of Veterans Affairs$3.38MApr 1, 2026
    140D0426F0156Department of the InteriorDepartmental Offices$2.62MApr 1, 2026
    36C25025N0894Department of Veterans AffairsDepartment of Veterans Affairs$2.60MSep 18, 2025
    36C26026F0304Department of Veterans AffairsDepartment of Veterans Affairs$2.38MJul 1, 2026
    36C26326N0588Department of Veterans AffairsDepartment of Veterans Affairs$2.02MJul 1, 2026
    36C26326N0214Department of Veterans AffairsDepartment of Veterans Affairs$1.92MOct 1, 2025
    36C24826N0003Department of Veterans AffairsDepartment of Veterans Affairs$1.91MOct 1, 2025
    36C25525N0393Department of Veterans AffairsDepartment of Veterans Affairs$1.85MAug 1, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors?

    Medtronic recently raised its quarterly dividend for the 49th consecutive year, albeit with a modest 1.4% increase...

    24/7 Wall St.•10/27/26•Neutral

    The Marzetti Company Names Mark Christenson President of Retail, Strengthens Retail Leadership Team to Accelerate Growth

    The Marzetti Company has appointed Mark Christenson as President of its Retail business, effective October 26, 2026, to lead sales, marketing...

    Morningstar•10/26/26•Somewhat-Bullish

    Abbott Laboratories stock outperforms competitors on strong trading day

    Shares of Abbott Laboratories (ABT) rose 1.14% to $104.88 on Monday, outperforming its competitors and the broader market. The S&P 500 Index (SPX) increased by 0.70%...

    MarketWatch•10/26/26•Bullish

    A genetic test tied to Alzheimer’s risk can now use urine, plasma or dried blood spots

    Niki BioSolutions (NASDAQ: NIKI) has received New York State approval to expand the specimen types for its APOE Genotyping test...

    Stock Titan•10/26/26•Somewhat-Bullish

    Bone Densitometer Devices Market Size, Forecast, Demand, Opportunities, 2034

    The global bone densitometer devices market was valued at USD 262.60 million in 2025 and is projected to reach USD 373.76 million by 2034, growing at a CAGR of 4.00%. North America held the largest market share in 2025...

    Straits Research•10/26/26•Somewhat-Bullish

    ABT Valuation and Fair Value

    P/E
    19.5x
    Forward P/E
    19.2x
    EV/EBITDA
    18.4x
    P/FCF
    23.3x
    PEG
    2.1x
    P/B
    3.6x
    See GNG's fair value

    ABT Profitability: Margins, ROIC and FCF

    Gross margin
    56.6%
    Operating margin
    11.3%
    Net margin
    9.8%
    ROIC
    6.9%
    ROE
    10.6%
    FCF margin
    16.8%
    FCF yield
    4.3%

    ABT Competitors

    CompanyTicker
    Gilead Sciences IncGILD
    Novo Nordisk A/SNVO
    Amgen IncAMGN
    Pfizer IncPFE
    Thermo Fisher Scientific IncTMO
    Danaher CorporationDHR
    AstraZeneca PLCAZN
    Intuitive Surgical IncISRG

    Sector: Healthcare

    ABT Analyst Ratings

    Consensus
    Buy
    Analysts
    27
    Strong Buy
    4
    Buy
    18
    Hold
    5
    Sell
    0
    Strong Sell
    0

    ABT Bull Case vs Bear Case

    Bull case

    • ABT converts 16.8% of revenue into free cash flow.
    • ABT grew quarterly revenue 14.5% year over year.
    • 81.5% of ABT's analyst ratings are Buy or Strong Buy.

    Bear case

    • ABT beat EPS estimates in 37.5% of its last 8 reported quarters.

    ABT Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    0.5%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $1.68

    ABT Dividend

    Forward yield
    2.4%
    Payout ratio
    44.3%
    3Y DPS growth
    7.9%
    5Y DPS growth
    10.4%
    Pay months
    Feb, May, Aug, Nov
    ABT dividend history

    Frequently Asked Questions About ABT

    What is ABT's current dividend yield?

    Abbott Laboratories (ABT) has a forward dividend yield of 2.40%.

    Does ABT pay dividends?

    Yes, Abbott Laboratories pays dividends with a forward dividend yield of 2.40%.

    What is ABT's P/E ratio?

    Abbott Laboratories has a price-to-earnings (P/E) ratio of 19.50.

    What is ABT's market cap?

    Abbott Laboratories (ABT) has a market capitalization of $180.63B with a current stock price of $104.89.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In